Two recent reports published in Leukemia have described the antibody response to SARS-CoV-2 infection in adult patients with chronic lymphocytic leukemia (CLL) and acute leukemia [2] in conjunction with PCR-confirmed COVID-19. These studies have demonstrated that 14/21 (67%) of the examined CLL patients and 7/8 (88%) of the examined acute leukemia patients produced anti-SARS-CoV-2 IgG antibodies. Importantly, 6 out of 7 IgG-positive acute leukemia patients developed virus-neutralizing antibodies, assuming a protective immune response.